Punicalagin is a neuraminidase inhibitor of influenza viruses
- J Med Virol. 2021 Jun;93(6):3465-3472. doi: 10.1002/jmv.26449.
- 1. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
- 2. Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao, China.
- 3. Research Center, College of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
- 4. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, China.
- 5. Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Influenza A virus (IAV) causes great morbidity and mortality worldwide every year. However, there are only a limited number of drugs clinically available against IAV Infection. Further, emergence of drug-resistant strains can render those drugs ineffective. Thus there is an unmet medical need to develop new anti-influenza agents. In this study, we show that punicalagin from Plants possesses strong anti-influenza activity with a low micromolar IC50 value in tissue culture. Using a battery of bioassays such as single-cycle replication assay, neuraminidase (NA) inhibition assay, and virus yield reduction assay, we demonstrate that the primary mechanism of action (MOA) of punicalagin is the NA-mediated viral release. Moreover, punicalagin can inhibit replication of different strains of influenza A and B viruses, including oseltamivir-resistant virus (NA/H274Y), indicating that punicalagin is a broad spectrum Antiviral against both IAV and IBV. Further, although punicalagin targets NA like oseltamivir, it has a different MOA. These results suggest that punicalagin is an influenza NA inhibitor that may be further developed as a novel Antiviral against influenza viruses.
-
Cat. No.Product NameCategory/Application